Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)

Jason Aldred; Eric Freire-Alvarez; Alexander V. Amelin; Angelo Antonini; Bruno Bergmans; Filip Bergquist; Manon Bouchard; Kumar Budur; Camille Carroll; K. Ray Chaudhuri; Susan R. Criswell; Erik H. Danielsen; Florin Gandor; Jia Jia; Thomas E. Kimber; Hideki Mochizuki; Weining Z. Robieson; Amy M. Spiegel; David G. Standaert; Saritha Talapala; Maurizio F. Facheris; Victor S.C. Fung

doi:10.1007/s40120-023-00554-w

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)

Jason Aldred^*, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha TalapalaMaurizio F. Facheris, Victor S.C. Fung

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morning…’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139, 25/125 and 56/125’ were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by…’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’ The original article has been corrected.

Original language	English
Pages (from-to)	1959-1960
Number of pages	2
Journal	Neurology and Therapy
Volume	12
Issue number	6
DOIs	https://doi.org/10.1007/s40120-023-00554-w
Publication status	Published - Dec 2023

Access to Document

10.1007/s40120-023-00554-w

Fingerprint

Dive into the research topics of 'Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)'. Together they form a unique fingerprint.

Cite this

Aldred, J., Freire-Alvarez, E., Amelin, A. V., Antonini, A., Bergmans, B., Bergquist, F., Bouchard, M., Budur, K., Carroll, C., Chaudhuri, K. R., Criswell, S. R., Danielsen, E. H., Gandor, F., Jia, J., Kimber, T. E., Mochizuki, H., Robieson, W. Z., Spiegel, A. M., Standaert, D. G., ... Fung, V. S. C. (2023). Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1). Neurology and Therapy, 12(6), 1959-1960. https://doi.org/10.1007/s40120-023-00554-w

Aldred, Jason ; Freire-Alvarez, Eric ; Amelin, Alexander V. et al. / Correction : Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1). In: Neurology and Therapy. 2023 ; Vol. 12, No. 6. pp. 1959-1960.

@article{2e4a457220cc4944b42d63d5e02cf83d,

title = "Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson{\textquoteright}s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)",

abstract = "In the sentences beginning {\textquoteleft}At baseline,…{\textquoteright} and {\textquoteleft}The reduction of early morning…{\textquoteright} in the section {\textquoteleft}Efficacy{\textquoteright} under the heading {\textquoteleft}Results{\textquoteright} in this article, the n/N values {\textquoteleft}129/238, 20/139, 25/125 and 56/125{\textquoteright} were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning {\textquoteleft}The reduction of “Off” time is particularly exemplified by…{\textquoteright} under the heading “Discussion”, the value {\textquoteleft}(changed from 17.5% at baseline to 63.0% at week 52){\textquoteright} should have read {\textquoteleft}(changed from 17.5% at baseline to 62.2% at week 52).{\textquoteright} The original article has been corrected.",

author = "Jason Aldred and Eric Freire-Alvarez and Amelin, {Alexander V.} and Angelo Antonini and Bruno Bergmans and Filip Bergquist and Manon Bouchard and Kumar Budur and Camille Carroll and Chaudhuri, {K. Ray} and Criswell, {Susan R.} and Danielsen, {Erik H.} and Florin Gandor and Jia Jia and Kimber, {Thomas E.} and Hideki Mochizuki and Robieson, {Weining Z.} and Spiegel, {Amy M.} and Standaert, {David G.} and Saritha Talapala and Facheris, {Maurizio F.} and Fung, {Victor S.C.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1007/s40120-023-00554-w",

language = "English",

volume = "12",

pages = "1959--1960",

journal = "Neurology and Therapy",

issn = "2193-8253",

publisher = "Springer Healthcare",

number = "6",

}

Aldred, J, Freire-Alvarez, E, Amelin, AV, Antonini, A, Bergmans, B, Bergquist, F, Bouchard, M, Budur, K, Carroll, C, Chaudhuri, KR, Criswell, SR, Danielsen, EH, Gandor, F, Jia, J, Kimber, TE, Mochizuki, H, Robieson, WZ, Spiegel, AM, Standaert, DG, Talapala, S, Facheris, MF & Fung, VSC 2023, 'Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)', Neurology and Therapy, vol. 12, no. 6, pp. 1959-1960. https://doi.org/10.1007/s40120-023-00554-w

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1). / Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V. et al.
In: Neurology and Therapy, Vol. 12, No. 6, 12.2023, p. 1959-1960.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)

AU - Aldred, Jason

AU - Freire-Alvarez, Eric

AU - Amelin, Alexander V.

AU - Antonini, Angelo

AU - Bergmans, Bruno

AU - Bergquist, Filip

AU - Bouchard, Manon

AU - Budur, Kumar

AU - Carroll, Camille

AU - Chaudhuri, K. Ray

AU - Criswell, Susan R.

AU - Danielsen, Erik H.

AU - Gandor, Florin

AU - Jia, Jia

AU - Kimber, Thomas E.

AU - Mochizuki, Hideki

AU - Robieson, Weining Z.

AU - Spiegel, Amy M.

AU - Standaert, David G.

AU - Talapala, Saritha

AU - Facheris, Maurizio F.

AU - Fung, Victor S.C.

PY - 2023/12

Y1 - 2023/12

N2 - In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morning…’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139, 25/125 and 56/125’ were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by…’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’ The original article has been corrected.

AB - In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morning…’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139, 25/125 and 56/125’ were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by…’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’ The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85173699760&partnerID=8YFLogxK

U2 - 10.1007/s40120-023-00554-w

DO - 10.1007/s40120-023-00554-w

M3 - Comment/debate

AN - SCOPUS:85173699760

SN - 2193-8253

VL - 12

SP - 1959

EP - 1960

JO - Neurology and Therapy

JF - Neurology and Therapy

IS - 6

ER -

Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F et al. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1). Neurology and Therapy. 2023 Dec;12(6):1959-1960. doi: 10.1007/s40120-023-00554-w

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this